Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

02/26/2024 - 04:30 PM

SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences.

Monday, March 4^th, Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer will participate in an IgA Nephropathy corporate panel at 9:10 am ET/6:10 am PT during the TD Cowen 44th Annual Healthcare Conference in Boston, MA and the Company will host investor meetings the same day.
Tuesday, March 12^th, Remy Durand, Ph.D., Chief Business Officer will participate in a fireside chat during the Leerink Partners Global Biopharma Conference in Miami, FL at 2:20 pm ET/11:20 am PT and the Company will host investor meetings the same day.

Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X and LinkedIn.